Drug Trial Radar · NCT07122453
Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Mar 2026
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Centrexion TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past. CNTX-3001 is a novel, non-opioid small molecule
Conditions
- Lower Back Pain
Interventions
CNTX-3001Drug
non-opioid analgesic
PlaceboDrug
Placebo product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse eventsTime frame: From baseline to the end of treatment visit (Day 7)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neurovations
Napa, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.